MetaCap

Relay Therapeutics Cash Flow Statement

NASDAQ: RLAYHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

17.88+0.47 (+2.70%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Relay Therapeutics free cash flow

In fiscal 2025, Relay Therapeutics generated -$235.5 million of operating cash flow and spent $410,000 on capital expenditures. That left free cash flow of -$235.9 million, a free-cash-flow margin of -1536.1% of revenue.

Summary generated from market data by MetaCap's automated system. Methodology

Relay Therapeutics cash flow statement (annual)

Relay Therapeutics annual cash flow statement
Fiscal year (USD)FY 20252025-12-31FY 20242024-12-31FY 20232023-12-31FY 20222022-12-31FY 20212021-12-31FY 20202020-12-31FY 20192019-12-31
Net Income-276.48M-337.71M-341.97M-290.51M-363.87M-52.41M-75.31M
Net Income growth (YoY)———————
Depreciation & Amortization3.56M5.46M5.27M4.13M3.92M3.55M2.85M
Stock-Based Compensation62.42M94.14M86.03M56.14M48.45M31.96M4.46M
Change in Working Capital-20.65M18.73M-27.04M12.59M90.63M-73.42M5.20M
Operating Cash Flow-235.46M-249.11M-300.32M-229.49M-74.41M-102.49M-66.13M
Capital Expenditures-410.00K-2.02M-4.13M-9.06M-3.47M-1.93M-8.00M
Investing Cash Flow192.80M-41.08M257.63M-188.75M-479.51M81.67M-319.02M
Financing Cash Flow1.60M270.15M34.75M289.91M388.09M426.51M5.61M
Net Change in Cash-41.05M-20.04M-7.93M-128.32M-165.83M405.69M-379.55M
Free Cash Flow-235.87M-251.13M-304.44M-238.55M-77.88M-104.42M-74.14M

This table shows 7 annual periods of Relay Therapeutics's cash flow statement, from FY 2025 back to FY 2019, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow RLAY's reporting calendar. What is a cash flow statement?

More financial data